Experience

neemen beauty GmbH

• Germany
• Cosmetics
• 1 - 100 Employee

• CSO and Co-Founder

  • Nov 2020 - Present



Biotechnology Consultant

• Cary, NC

• Independent Biotechnology Consultant

  • Jan 2005 - Present

  I provide consulting in the following areas: • Hemophilia, plasma Factor VIII, recombinant FVIII, alpha1-Antitrypsin, immunoglobulins, IVIG, protein drug development, manufacturing processes development and improvement. • Protein chemistry, blood/plasma, coagulation, fibrinolysis, immunology, plasma fractionation, cell culture, pathogen safety, assay development. • Drug discovery, and preclinical drug development with pharmacology, from concept discovery to IND. • Purification process and manufacturing process development/improvement for recombinant and plasma-derived protein therapeutics. • Technology assessment. • Subject matter expert. • Intellectual property analysis for FTO and management of IP. • Management of interactions with CROs and CMOs, with due diligence & alliance building • Extensive scientific and professional network across the coagulation, plasma and recombinant protein industry, academia and international health care professionals • Excellent communication and presentation skills in English and in German Show less



JustNeem, LLC

• United States
• Personal Care Product Manufacturing
• 1 - 100 Employee

• CEO

  • Apr 2007 - Present

  Development and manufacture of Skin Care Products with Neem for conditions including dry skin, eczema, acne, psoriasis, rosacea, dermatitis, etc.. Wholesale distribution and direct sale of Neem Skin Care Products. Neem tree planting, reforestation, and creation of Neem-based economic opportunities, in West Africa, that serve underprivileged populations. Current focus on Mauritania. www.justneem.com Development and manufacture of Skin Care Products with Neem for conditions including dry skin, eczema, acne, psoriasis, rosacea, dermatitis, etc.. Wholesale distribution and direct sale of Neem Skin Care Products. Neem tree planting, reforestation, and creation of Neem-based economic opportunities, in West Africa, that serve underprivileged populations. Current focus on Mauritania. www.justneem.com



Grifols

• Spain
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Principal Process Development Scientist

  • Sep 2011 - Feb 2013

  Team leader for purification process development of recombinant FVIII from Per.C6 cell cultures. Developed bench-scale process and scale-up for tox lot production. Developed parameters for plasma collection to optimize product recovery. Developed concept for isoagglutinin-free IgM product for treatment of systemic bacteremia. Developed concept of oral IgA/IgM product for treatment of GI infections. Team leader for purification process development of recombinant FVIII from Per.C6 cell cultures. Developed bench-scale process and scale-up for tox lot production. Developed parameters for plasma collection to optimize product recovery. Developed concept for isoagglutinin-free IgM product for treatment of systemic bacteremia. Developed concept of oral IgA/IgM product for treatment of GI infections.



Talecris Biotherapeutics, Inc.

• United States
• Biotechnology
• 200 - 300 Employee

• Principal Process Development Scientist

  • Apr 2009 - Aug 2010

  Developed scaled-down model of commercial manufacturing process for plasma-derived Factor VIII from cyro precipitate. Developed filtration and chromatography unit operations to improve robustness, throughput, and product recovery. Subject Matter Expert for manufacturing incident investigations. Developed scaled-down model of commercial manufacturing process for plasma-derived Factor VIII from cyro precipitate. Developed filtration and chromatography unit operations to improve robustness, throughput, and product recovery. Subject Matter Expert for manufacturing incident investigations.



Biolex

• Biotechnology
• 1 - 100 Employee

• Associate Director of Research

  • Jul 2005 - Feb 2008

  Developed purification processes and analytical methods for recombinant biotherapeutics produced in Lemna minor, an aquatic plant. Process development, scale up to macro-bench and pilot scale, preclinical studies, pharmacology models, toxicology studies, IND submission. Developed purification processes and analytical methods for recombinant biotherapeutics produced in Lemna minor, an aquatic plant. Process development, scale up to macro-bench and pilot scale, preclinical studies, pharmacology models, toxicology studies, IND submission.



Bayer

• Chemical Manufacturing
• 700 & Above Employee

• Sr. Staff Scienst II

  • Feb 1997 - Jun 2005

  Identified therapeutic opportunities for proteins from human plasma, including paraoxonase, a2-antiplasmin, plasminongen, a2-macroglobulin, gelsolin, IgA, IgM, transferrin, a1-acid glycoprotein, thrombin, and fibrin(ogen). Purified proteins from human plasma. Identified animal models and collaborated with CROs and universities for proof of concept studies. Project lead for recombinant FVIII mutants with prolonged half-life and or prolonged activity. Managed collaborations with external investigators at Scripps Research Institute, American Red Cross, University of Michigan, and several others. Identified and secured relevant IP. Filed 6 patents, including patent for Gamunex. Show less



Goethe University Frankfurt

• Germany
• Higher Education
• 700 & Above Employee

• Director of Research

  • Nov 1993 - Jan 1997

  Identified protein C inhibitor in human pancreas tissue and pancreatic fluid. Studied protein C inhibitor in human cancer tissues. Developed a PCR-based assay for the thrombogenic coagulation factor FV Leiden mutation R506Q. Screened thrombosis patient plasma for the presence of the FVIII Leiden mutation. Identified protein C inhibitor in human pancreas tissue and pancreatic fluid. Studied protein C inhibitor in human cancer tissues. Developed a PCR-based assay for the thrombogenic coagulation factor FV Leiden mutation R506Q. Screened thrombosis patient plasma for the presence of the FVIII Leiden mutation.



Scripps Research

• United States
• Research Services
• 700 & Above Employee

• Postdoctoral Research Associate

  • Sep 1988 - Nov 1993

  Cloned protein C inhibitor and a2-antiplasmin from human liver cDNA. Expressed PCI in E. coli. Performed structure-function studies, electron microscopy, in situ hybridization and immunoflourescense microscopy, to demonstrate transcription and expression of PCI in different human tissues. Obtained 1 patent. Cloned protein C inhibitor and a2-antiplasmin from human liver cDNA. Expressed PCI in E. coli. Performed structure-function studies, electron microscopy, in situ hybridization and immunoflourescense microscopy, to demonstrate transcription and expression of PCI in different human tissues. Obtained 1 patent.



Behringwerke AG Marburg

• Research Assistant, Aventis-Behring

  • Jan 1987 - Aug 1988

  Developed a purification process for plasminogen inhibitor-2 (PAI-2) from human placenta tissue. Developed a commercial chromogenic assay for protein C in human plasma on a new instrument platform (Chromotimer). Obtained 1 patent.

• Doctoral Fellow

  • Mar 1983 - Jan 1987

  Developed a purification process for protein C inhibitor (PCI) from human plasma. Performed characterization studies of this newly discovered regulator of protein C and showed that it also inhibits urokinase. Obtained 2 patents.



The Philipp University of Marburg

• Higher Education
• 700 & Above Employee

• Graduate Student

  • Jan 1982 - Feb 1983

  Developed a quantitative immuno electrophoresis assay for a2-antiplasmin-elastase complexes in human plasma. Studied a2-antiplasmin-elastase complex levels in plasma of sepsis patients. Developed a quantitative immuno electrophoresis assay for a2-antiplasmin-elastase complexes in human plasma. Studied a2-antiplasmin-elastase complex levels in plasma of sepsis patients.